

DAFTAR PUSTAKA

- Abrams, C.S. 2021, *Official reprint from UpToDate*®, pp. 1–12.
- Akhondzadeh, S. 2014, 'Personalized medicine: a tailor made medicine', *Avicenna Journal of Medical Biotechnology*, vol. 6, no. 4, p. 191.
- Al-Koofee, D.A.. & Mubarak, S.M.. 2019, 'Genetic Polymorphisms', *Intech*, vol. 32, pp. 137–44.
- Alhazzani, A.A., Munisamy, M. & Karunakaran, G. 2017, 'Pharmacogenetics of CYP2C19 genetic polymorphism on clopidogrel response in patients with ischemic stroke from Saudi Arabia', *Neurosciences*, vol. 22, no. 1, pp. 31–7.
- Amin, A.M., Sheau Chin, L., Azri Mohamed Noor, D., Sk Abdul Kader, M.A., Kah Hay, Y. & Ibrahim, B. 2017, 'The Personalization of Clopidogrel Antiplatelet Therapy: The Role of Integrative Pharmacogenetics and Pharmacometabolomics', *Cardiology Research and Practice*, vol. 2017.
- Ancrenaz, V., Desmeules, J., James, R., Fontana, P., Reny, J.L., Dayer, P. & Daali, Y. 2012, 'The paraoxonase-1 pathway is not a major bioactivation pathway of clopidogrel in vitro', *British Journal of Pharmacology*, vol. 166, no. 8, pp. 2362–70.
- Angiolillo, D.J., Fernandez-Ortiz, A., Bernardo, E., Alfonso, F., Macaya, C., Bass, T.A. & Costa, M.A. 2007, 'Variability in Individual Responsiveness to Clopidogrel. Clinical Implications, Management, and Future Perspectives', *Journal of the American College of Cardiology*, vol. 49, no. 14, pp. 1505–16.
- Bachtiar, M. & Lee, C.G.L. 2013, 'Genetics of Population Differences in Drug Response', *Current Genetic Medicine Reports*, vol. 1, no. 3, pp. 162–70.
- Cacabelos, R. 2012, 'The Metabolomic Paradigm of Pharmacogenomics in Complex Disorders', *Metabolomics*.
- Cavallari, L.H., Lee, C.R., Beitelshes, A.L., Cooper-DeHoff, R.M., Duarte, J.D., Voora, D., Kimmel, S.E., McDonough, C.W., Gong, Y., Dave, C. V., Pratt, V.M., Alestock, T.D., Anderson, R.D., Alsip, J., Ardati, A.K., Brott, B.C.,

- Brown, L., Chumnumwat, S., Clare-Salzler, M.J., Coons, J.C., Denny, J.C., Dillon, C., Else, A.R., Hamadeh, I.S., Harada, S., Hillegass, W.B., Hines, L., Horenstein, R.B., Howell, L.A., Jeng, L.J.B., Kelemen, M.D., Lee, Y.M., Magvanjav, O., Montasser, M., Nelson, D.R., Nutescu, E.A., Nwaba, D.C., Pakyz, R.E., Palmer, K., Peterson, J.F., Pollin, T.I., Quinn, A.H., Robinson, S.W., Schub, J., Skaar, T.C., Smith, D.M., Sriramoju, V.B., Starostik, P., Stys, T.P., Stevenson, J.M., Varunok, N., Vesely, M.R., Wake, D.T., Weck, K.E., Weitzel, K.W., Wilke, R.A., Willig, J., Zhao, R.Y., Kreutz, R.P., Stouffer, G.A., Empey, P.E., Limdi, N.A., Shuldiner, A.R., Winterstein, A.G. & Johnson, J.A. 2018, 'Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention', *JACC: Cardiovascular Interventions*, vol. 11, no. 2, pp. 181–91.
- Chan, M.Y. & Tan, H. 2012, *Research Article CYP2C19 and PON1 polymorphisms regulating clopidogrel bioactivation in Chinese, Malay and Indian subjects Research Article*, pp. 533–42.
- Chen, Y. bei, Zhou, Z. yi, Li, G. min, Xiao, C. xing, Yu, W. bang, Zhong, S. long, Cai, Y. feng, Jin, J. & Huang, M. 2019, 'Influences of an NR1I2 polymorphism on heterogeneous antiplatelet reactivity responses to clopidogrel and clinical outcomes in acute ischemic stroke patients', *Acta Pharmacologica Sinica*, vol. 40, no. 6, pp. 762–8.
- Damman, P., Woudstra, P., Kuijt, W.J., De Winter, R.J. & James, S.K. 2012, 'P2Y12 platelet inhibition in clinical practice', *Journal of Thrombosis and Thrombolysis*, vol. 33, no. 2, pp. 143–53.
- Dorji, P.W., Tshering, G. & Na-Bangchang, K. 2019, 'CYP2C9, CYP2C19, CYP2D6 and CYP3A5 polymorphisms in South-East and East Asian populations: A systematic review', *Journal of Clinical Pharmacy and Therapeutics*, vol. 44, no. 4, pp. 508–24.
- Erlinge, D., James, S., Duvvuru, S., Jakubowski, J.A., Wagner, H., Varenhorst, C., Tantry, U.S., Brown, P.B., Small, D., Moser, B.A., Sundseth, S.S., Walker,

- J.R., Winters, K.J. & Gurbel, P.A. 2014, 'Clopidogrel metaboliser status based on point-of-care CYP2C19 genetic testing in patients with coronary artery disease', *Thrombosis and Haemostasis*, vol. 111, no. 5, pp. 943–50.
- Farid, N.A., Smith, R.L., Gillespie, T.A., Rash, T.J., Blair, P.E., Kurihara, A. & Goldberg, M.J. 2007, 'The disposition of prasugrel, a novel thienopyridine, in humans', *Drug Metabolism and Disposition*, vol. 35, no. 7, pp. 1096–104.
- Galeazzi, R., Olivieri, F., Spazzafumo, L., Rose, G., Montesanto, A., Giovagnetti, S., Cecchini, S., Malatesta, G., Di Pillo, R. & Antonicelli, R. 2018, 'Clustering of ABCB1 and CYP2C19 Genetic Variants Predicts Risk of Major Bleeding and Thrombotic Events in Elderly Patients with Acute Coronary Syndrome Receiving Dual Antiplatelet Therapy with Aspirin and Clopidogrel', *Drugs and Aging*, vol. 35, no. 7, pp. 649–56.
- Gurbel, P.A., Bergmeijer, T.O., Tantry, U.S., Ten Berg, J.M., Angiolillo, D.J., James, S., Lindahl, T.L., Svensson, P., Jakubowski, J.A., Brown, P.B., Duvvuru, S., Sundseth, S., Walker, J.R., Small, D., Moser, B.A., Winters, K.J. & Erlinge, D. 2014, 'The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease', *Thrombosis and Haemostasis*, vol. 112, no. 3, pp. 589–97.
- Harmsze, A.M., van Werkum, J.W., Hackeng, C.M., Ruven, H.J.T., Kelder, J.C., Bouman, H.J., Breet, N.J., Ten Berg, J.M., Klungel, O.H., de Boer, A. & Deneer, V.H.M. 2012, 'The influence of CYP2C19*2 and *17 on on-treatment platelet reactivity and bleeding events in patients undergoing elective coronary stenting.', *Pharmacogenetics and genomics*, vol. 22, no. 3, pp. 169–75.
- Hayati, L. & Yoga, F.S. 2018, 'Prevalensi Polimorfisme Gen CYP2C19 dan Pengaruhnya Dalam Metabolisme Omeprazole Sebagai Prediktor Intoksikasi Obat Pada Etnis Melayu Di Sumatera Selatan Abstrak gen didapatkan selama perkembangan evolusi melalui berbagai', *Sriwijaya Journal of Medicine*, vol. 1, no. 2, pp. 108–14.
- Ismail, S. & Essawi, M. 2012, 'Genetic polymorphism studies in humans', *Middle*

East Journal of Medical Genetics, vol. 1, no. 2, pp. 57–63.

Jain, K.K. 2015, *Textbook of Personalized Medicine, Textbook of Personalized Medicine*.

Jeong, Y.H., Tantry, U.S., Kim, I.S., Koh, J.S., Kwon, T.J., Park, Y., Hwang, S.J., Bliden, K.P., Kwak, C.H., Hwang, J.Y. & Gurbel, P.A. 2011, 'Effect of CYP2C19 *2 and *23 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin', *Circulation: Cardiovascular Interventions*, vol. 4, no. 6, pp. 585–94.

Jia, D.M., Chen, Z. Bin, Zhang, M.J., Yang, W.J., Jin, J.L., Xia, Y.Q., Zhang, C.L., Shao, Y., Chen, C. & Xu, Y. 2013, 'CYP2C19 polymorphisms and antiplatelet effects of clopidogrel in acute ischemic stroke in China', *Stroke*, vol. 44, no. 6, pp. 1717–9.

Karaźniewicz-Łada, M., Danielak, D., Rubiś, B., Burchardt, P., Oszkinis, G. & Głowska, F. 2014, 'The influence of genetic polymorphism of Cyp2c19 isoenzyme on the pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases', *Journal of Clinical Pharmacology*, pp. 874–80.

Kazui, M., Nishiya, Y., Ishizuka, T., Hagihara, K., Farid, N.A., Okazaki, O., Ikeda, T. & Kurihara, A. 2010, 'Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite', *Drug Metabolism and Disposition*, vol. 38, no. 1, pp. 92–9.

Kelly, R.P., Close, S.L., Farid, N.A., Winters, K.J., Shen, L., Natanegara, F., Jakubowski, J.A., Ho, M., Walker, J.R. & Small, D.S. 2012, 'Pharmacokinetics and pharmacodynamics following maintenance doses of prasugrel and clopidogrel in Chinese carriers of CYP2C19 variants', *British Journal of Clinical Pharmacology*, vol. 73, no. 1, pp. 93–105.

Kim, H.S., Lim, Y., Oh, M., Ghim, J.L., Kim, E.Y., Kim, D.H. & Shin, J.G. 2016, 'The pharmacokinetic and pharmacodynamic interaction of clopidogrel and

cilostazol in relation to CYP2C19 and CYP3A5 genotypes', *British Journal of Clinical Pharmacology*, vol. 81, no. 2, pp. 301–12.

Lamoureux, F. & Duflot, T. 2017, 'Pharmacogenetics in cardiovascular diseases: State of the art and implementation-recommendations of the French National Network of Pharmacogenetics (RNPGx)', *Therapie*, vol. 72, no. 2, pp. 257–67.

Langae, T.Y., Zhu, H.J., Wang, X., El Rouby, N., Markowitz, J.S., Goldstein, J.A. & Johnson, J.A. 2014, 'The influence of the CYP2C19*10 allele on clopidogrel activation and CYP2C19*2 genotyping', *Pharmacogenetics and Genomics*, vol. 24, no. 8, pp. 381–6.

Lee, C.R., Pharm, D., Sriramoju, V.B., Cervantes, A., Howell, L.A., Varunok, N., Madan, S., Hamrick, K., Pharm, D., Polasek, M.J., Pharm, D., Lee, J.A., Pharm, D., Clarke, M., Pharm, D., Cicci, J.D., Pharm, D., Weck, K.E. & Stouffer, G.A. 2019, *Clinical Outcomes and Sustainability of Using CYP2C19 Genotype-guided Antiplatelet Therapy after Percutaneous Coronary Intervention*, vol. 11, no. 4, pp. 1–21.

Li, Y.J., Chen, X., Tao, L.N., Hu, X.Y., Wang, X.L. & Song, Y.Q. 2021, 'Association between CYP2C19 polymorphisms and clinical outcomes in patients undergoing stent procedure for cerebral artery stenosis', *Scientific Reports*, vol. 11, no. 1, pp. 1–7.

Madian, A.G., Wheeler, H.E. Jones, R.B. & Dolan, M. 2013, *Human genetic variation + drug responses*, vol. 28, no. 10, pp. 487–95.

Man, M., Farmen, M., Dumauual, C., Teng, C.H., Moser, B., Irie, S., Noh, G.J., Njau, R., Close, S., Wise, S. & Hockett, R. 2010, 'Genetic variation in metabolizing enzyme and transporter genes: Comprehensive assessment in 3 major East Asian subpopulations with comparison to Caucasians and Africans', *Journal of Clinical Pharmacology*, vol. 50, no. 8, pp. 929–40.

Mao, L., Jian, C., Changzhi, L., Dan, H., Suihua, H., Wenyi, T. & Wei, W. 2013, 'Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: A meta-analysis based on 23,035 subjects',

Archives of Cardiovascular Diseases, vol. 106, no. 10, pp. 517–27.

- McFadyen, J.D., Schaff, M. & Peter, K. 2018, 'Current and future antiplatelet therapies: Emphasis on preserving haemostasis', *Nature Reviews Cardiology*, vol. 15, no. 3, pp. 181–91.
- Mega, J.L., Close, S.L., Wiviott, S.D., Shen, L., Hockett, R.D., Brandt, J.T., Walker, J.R., Antman, E.M., Macias, W., Braunwald, E. & Sabatine, M.S. 2009, 'Cytochrome p-450 polymorphisms and response to clopidogrel.', *Current atherosclerosis reports*, vol. 11, no. 3, pp. 157–60.
- Mirabbasi, S. abbas, Khalighi, K., Wu, Y., Walker, S., Khalighi, B., Fan, W., Kodali, A. & Cheng, G. 2017, 'CYP2C19 genetic variation and individualized clopidogrel prescription in a cardiology clinic', *Journal of Community Hospital Internal Medicine Perspectives*, vol. 7, no. 3, pp. 151–6.
- Montalescot, G. 2011, 'Platelet biology and implications for antiplatelet therapy in atherothrombotic disease', *Clinical and Applied Thrombosis/Hemostasis*, vol. 17, no. 4, pp. 371–80.
- Niu, X., Mao, L., Huang, Y., Baral, S., Li, J.Y., Gao, Y., Xia, Y.P., He, Q.W., Wang, M.D., Li, M., Zou, L., Miao, X. ping & Hu, B. 2015, 'CYP2C19 polymorphism and clinical outcomes among patients of different races treated with clopidogrel: A systematic review and meta-analysis', *Journal of Huazhong University of Science and Technology - Medical Science*, vol. 35, no. 2, pp. 147–56.
- Pan, Y., Chen, W., Xu, Y., Yi, X., Han, Y., Yang, Q., Li, X., Huang, L., Johnston, S.C., Zhao, X., Liu, L., Zhang, Q., Wang, G., Wang, Yongjun & Wang, Yilong 2017, 'Genetic polymorphisms and clopidogrel efficacy for acute ischemic stroke or transient ischemic attack', *Circulation*, vol. 135, no. 1, pp. 21–33.
- Park, M.W., Her, S.H., Kim, H.S., Choi, Y.S., Park, C.S., Koh, Y.S., Park, H.J., Kim, P.J., Kim, C.J., Jeon, D.S., Shin, D. Il, Seo, S.M., Yoo, K.D., Kim, D. Bin, Kim, H.Y., Lee, J.M., Chung, W.S., Seung, K.B., Shin, J.G. & Chang, K. 2013, 'Impact of the CYP2C19*17 polymorphism on the clinical outcome of clopidogrel therapy in Asian patients undergoing percutaneous coronary

- intervention', *Pharmacogenetics and Genomics*, vol. 23, no. 10, pp. 558–62.
- Peng, W., Shi, X., Xu, X. & Lin, Y. 2019, 'Both CYP2C19 and PON1 Q192R Genotypes Influence Platelet Response to Clopidogrel by Thrombelastography in Patients with Acute Coronary Syndrome', *Cardiovascular Therapeutics*, vol. 2019.
- PharmGKB 2021, *Clopidogrel*, viewed <<https://www.pharmgkb.org/chemical/PA449053/clinicalAnnotation>>.
- PharmVar 2021, *Pharmacogene Variation Consortium*, viewed <<https://www.pharmvar.org/gene/CYP2C19>>.
- Price, M.J., Berger, P.B., Teirstein, P.S., Tanguay, J.F., Angiolillo, D.J., Spriggs, D., Puri, S., Robbins, M., Garratt, K.N., Bertrand, O.F., Stillablower, M.E., Aragon, J.R., Kandzari, D.E., Stinis, C.T., Lee, M.S., Manoukian, S. V., Cannon, C.P., Schork, N.J. & Topol, E.J. 2011, 'Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: The GRAVITAS randomized trial', *JAMA - Journal of the American Medical Association*, vol. 305, no. 11, pp. 1097–105.
- Sangkuhl, K., Kleima, T.E. & Altmana, R.. 2011, *Clopidogrel Pathway - NIH Public Access*, vol. 4, no. 164, pp. 463–5.
- Schömig, A. 2009, 'Ticagrelor — Is There Need for a New Player in the Antiplatelet-Therapy Field?', *New England Journal of Medicine*, vol. 361, no. 11, pp. 1108–11.
- Scott, S.A., Martis, S., Peter, I., Kasai, Y., Kornreich, R. & Desnick, R.J. 2012, 'Identification of CYP2C19*4B: Pharmacogenetic implications for drug metabolism including clopidogrel responsiveness', *Pharmacogenomics Journal*, vol. 12, no. 4, pp. 297–305.
- Scott, S.A., Sangkuhl, K., Stein, C.M., Hulot, J.S., Mega, J.L., Roden, D.M., Klein, T.E., Sabatine, M.S., Johnson, J.A. & Shuldiner, A.R. 2013, 'Clinical pharmacogenetics implementation consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update', *Clinical Pharmacology and*

Therapeutics, vol. 94, no. 3, pp. 317–23.

- Shavelle, D.M. 2016, 'Newer P2Y₁₂ Inhibitors: How Does the Interventional Cardiologist Choose?', *Journal of the American Heart Association*, vol. 5, no. 9, pp. 10–2.
- Sibbing, D., Koch, W., Gebhard, D., Schuster, T., Braun, S., Stegherr, J., Morath, T., Schömig, A., Von Beckerath, N. & Kastrati, A. 2010, 'Cytochrome 2c19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement', *Circulation*, vol. 121, no. 4, pp. 512–8.
- Siller-Matula, J.M., Trenk, D., Krähenbühl, S., Michelson, A.D. & Delle-Karth, G. 2014, 'Clinical implications of drug-drug interactions with P2Y₁₂ receptor inhibitors', *Journal of Thrombosis and Haemostasis*, vol. 12, no. 1, pp. 2–13.
- Simon, T., Bhatt, D.L., Bergougnan, L., Farenc, C., Pearson, K., Perrin, L., Vicaut, E., Lacreta, F., Hurbin, F. & Dubar, M. 2011, 'Genetic polymorphisms and the impact of a higher clopidogrel dose regimen on active metabolite exposure and antiplatelet response in healthy subjects', *Clinical Pharmacology and Therapeutics*, vol. 90, no. 2, pp. 287–95.
- Song, B.L., Wan, M., Tang, D., Sun, C., Zhu, Y.B., Linda, N., Fan, H.W. & Zou, J.J. 2018, 'Effects of CYP2C19 Genetic Polymorphisms on the Pharmacokinetic and Pharmacodynamic Properties of Clopidogrel and Its Active Metabolite in Healthy Chinese Subjects', *Clinical Therapeutics*, vol. 40, no. 7, pp. 1170–8.
- Takahashi, M., Saito, T., Ito, M., Tsukada, C., Katono, Y., Hosono, H., Maekawa, M., Shimada, M., Mano, N., Oda, A., Hirasawa, N. & Hiratsuka, M. 2015, 'Functional characterization of 21 CYP2C19 allelic variants for clopidogrel 2-oxidation', *Pharmacogenomics Journal*, vol. 15, no. 1, pp. 26–32.
- Tan, D.S.Y., Aw, J.W.X., Winther, M., Goh, L.L., Ong, H.Y., Wee, E., Liu, J. & Ho, H.K. 2020, 'CYP2C19 phenotype in South-East Asian Acute Coronary Syndrome patients and impact on major adverse cardiovascular events', *Journal of Clinical Pharmacy and Therapeutics*, vol. 45, no. 1, pp. 52–8.

- The Dutch Pharmacogenetics Working Group Guideline 2020, 'Pharmacogenomic recommendations, farmacogenetica-update', *經濟志林*, vol. 87, no. 1,2, pp. 149–200.
- Turner, R.M., Park, B.K. & Pirmohamed, M. 2015, 'Parsing interindividual drug variability: An emerging role for systems pharmacology', *Wiley Interdisciplinary Reviews: Systems Biology and Medicine*, vol. 7, no. 4, pp. 221–41.
- Verschuren, J.J.W., Boden, H., Wessels, J.A.M., Van Der Hoeven, B.L., Trompet, S., Heijmans, B.T., Putter, H., Guchelaar, H.J., Schalijs, M.J. & Jukema, J.W. 2013, 'Value of platelet pharmacogenetics in common clinical practice of patients with ST-segment elevation myocardial infarction', *International Journal of Cardiology*, vol. 167, no. 6, pp. 2882–8.
- Wake, D.T., Ilbawi, N., Dunnenberger, H.M. & Hulick, P.J. 2019, 'Pharmacogenomics: Prescribing Precisely', *Medical Clinics of North America*, vol. 103, no. 6, pp. 977–90.
- Wallentin, L., James, S., Storey, R.F., Armstrong, M., Barratt, B.J., Horrow, J., Husted, S., Katus, H., Steg, P.G., Shah, S.H. & Becker, R.C. 2010, 'Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: A genetic substudy of the PLATO trial', *The Lancet*, vol. 376, no. 9749, pp. 1320–8.
- Wang, A. 2013, 'Cangrelor: A New Kind of Antiplatelet Therapy', *Journal of Developing Drugs*, vol. 02, no. 03, pp. 2–3.
- Whirl-Carrillo, M., McDonagh, E.M., Hebert, J.M., Gong, L., Sangkuhl, K., Thorn, C.F., Altman, R.B. & Klein, T.E. 2012, 'Pharmacogenomics knowledge for personalized medicine', *Clinical Pharmacology and Therapeutics*, vol. 92, no. 4, pp. 414–7.
- Xi, Z., Fang, F., Wang, J., AlHelal, J., Zhou, Y. & Liu, W. 2019, 'CYP2C19 genotype and adverse cardiovascular outcomes after stent implantation in

clopidogrel-treated Asian populations: A systematic review and meta-analysis', *Platelets*, vol. 30, no. 2, pp. 229–40.

Xi, Z., Zhou, Y., Zhao, Y., Liu, X., Liang, J., Chai, M., Yu, Y. & Liu, W. 2020, 'Ticagrelor Versus Clopidogrel in Patients with Two CYP2C19 Loss-of-Function Alleles Undergoing Percutaneous Coronary Intervention', *Cardiovascular Drugs and Therapy*, vol. 34, no. 2, pp. 179–88.

Xie, C., Ding, X., Gao, J., Wang, H., Hang, Y., Zhang, H., Zhang, J., Jiang, B. & Miao, L. 2014, 'The effects of CES1A2 A(-816)C and CYP2C19 loss-of-function polymorphisms on clopidogrel response variability among Chinese patients with coronary heart disease', *Pharmacogenetics and Genomics*, vol. 24, no. 4, pp. 204–10.

Zhang, H.Z., Kim, M.H., Guo, L.Z. & Serebruany, V. 2017, 'CYP2C19 but not CYP2B6, CYP3A4, CYP3A5, ABCB1, PON1 or P2Y12 genetic polymorphism impacts antiplatelet response after clopidogrel in Koreans', *Blood Coagulation and Fibrinolysis*, vol. 28, no. 1, pp. 56–61.

Zhu, W.Y., Zhao, T., Xiong, X.Y., Li, J., Wang, L., Zhou, Y., Gong, Z.L., Cheng, S.Y., Liu, Y., Shuai, J. & Yang, Q.W. 2016, 'Association of CYP2C19 Polymorphisms with the Clinical Efficacy of Clopidogrel Therapy in Patients Undergoing Carotid Artery Stenting in Asia', *Scientific Reports*, vol. 6, no. May, pp. 21–3.

Zou, J.J., Tan, J., Fan, H.W. & Chen, S.L. 2012, 'Bioequivalence study of clopidogrel 75 Mg tablets in healthy male volunteers', *Journal of Bioequivalence and Bioavailability*, vol. 4, no. 1, pp. 006–9.